Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The candidate, dubbed onvansertib, is being tested among patients with first-line RAS-mutated metastatic ... patients with non-small cell lung cancer and a genetic mutation dubbed KRAS G12C ...

Many cancers, including PDAC, are driven by mutations in the RAS family of oncogenes – genes that, when altered, promote cancer. Researchers have long sought drugs that target the actions of mutant ...

Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the most commonly activated genes in cancer – causes cells ...

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

These findings have important implications for congenital disorders, cancer, and aging ... Errors can occur when genetic material is copied, creating "unfit" cells that don't work properly.

While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

Errors can occur when genetic material is copied ... including those with abnormal Wnt, Shh, or oncogenic Ras signaling, or those with low pluripotency, abnormal ribosomes, or mitochondrial ...

Oncolytic viruses work by injecting genetic material into ... is planning a phase 2 trial of its RAS neoantigen vaccine TG01, targeting resected pancreatic cancer in combination with a checkpoint ...

001), according to findings from a prespecified, exploratory analysis of the KEYNOTE-522 study (NCT03036488) in high-risk, early triple-negative breast cancer ... gene expression profile consensus ...